A PHASE 1, OPEN-LABEL, RANDOMIZED, CROSSOVER, SINGLE DOSE STUDY TO DETERMINE THE BIOEQUIVALENCE OF 12.2 MG TAFAMIDIS FREE ACID TABLET AND COMMERCIAL 20 MG TAFAMIDIS MEGLUMINE CAPSULE ADMINISTERED UNDER FASTED CONDITIONS TO HEALTHY PARTICIPANTS
Latest Information Update: 09 Mar 2021
At a glance
- Drugs Tafamidis meglumine (Primary) ; Tafamidis meglumine
- Indications Amyloid polyneuropathy; Cardiomyopathies
- Focus Pharmacokinetics
- Sponsors Pfizer
- 04 Mar 2021 Status changed from recruiting to completed.
- 07 Oct 2020 New trial record